On 24 April 2015, orphan designation (EU/3/15/1484) was granted by the European Commission to Biological Consulting Europe Ltd, United Kingdom, for nitric oxide for the treatment of cystic fibrosis.
Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in March 2019 on request of the Sponsor.
|Disease / condition||
Treatment of cystic fibrosis
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;